Elisa Scarselli
Chief Scientific Officer Nouscom
Dr Elisa Scarselli is the Chief Scientific Officer and co-founder of Nouscom, where she leads the development of novel cancer immunotherapy vaccines based on neoantigen platforms. A medical doctor with a background in hematology, she has over 30 years of experience in immunology, virology, and oncology, spanning roles at IRBM/Merck and Okairos. She has driven vaccine programs from preclinical research through clinical trial design and regulatory submission, and is widely published in the field of immunotherapy and infectious diseases.
Seminars
Thursday 23rd July 2026
Exploring the Benefits of Nous-209 Neoantigen Vaccine for Cancer Prevention in Lynch Syndrome Carriers
12:00 pm
- In LS carriers, immunotheraphy with NOUS-209 off the shelf vaccine is safe and well tolerated
- NOUS-209 elicits robust neoantigen specific T-cell response in 100% of subjects
- Vaccine-induced responses are broad and recognised multiple neoantigens
